| Literature DB >> 16527311 |
Jacob H Chung1, Gregory P Van Stavern, Larry P Frohman, Roger E Turbin.
Abstract
We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of anti-tumor necrosis factor-alpha (TNF-alpha) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16527311 DOI： 10.1016/j.jns.2006.01.012
Source DB: PubMed Journal: J Neurol Sci ISSN： 0022-510X Impact factor: 3.181